Cutaneous malignant melanoma is a serious healthcare problem with >55,100 new cases anticipated in 2004 in the U.S., with a mortality rate of about 14.5% (1). The incidence of melanoma continues to increase faster than that of any other malignancy (2). Although the prognosis for early local melanoma is favorable with 5-year overall survival of >90%, regional lymph node involvement decreases the overall survival rate by 10% to 46% (3). Therefore, regional lymph node status becomes the most significant prognostic factor for a melanoma patient’s survival. Introduction of the sentinel lymph nodes technique (4) has increased the sensitivity of melanoma micrometastasis detection compared to H&E staining alone (5, 6). Nevertheless, even with enhanced by immunohistochemistry, histologic analysis is limited by the ability of light microscopy to recognize the tumor cells. Reverse transcription-PCR (RT-PCR) analysis has recently been proposed for a more sensitive detection of melanoma cells in lymph nodes. Many studies, when using well-characterized melanocyte-specific markers, such as tyrosinase and MART-1, have shown the presence of these gene transcripts in the lymph node, which were negative when using routine histologic and immunohistochemical methods (7, 8). However, these genes are not specific to tumor cells and cannot be used to discriminate between benign and malignant tissue. In fact, they cause false-positive results in the presence of benign capsular nevi (9–11). Considering that benign nevi are not rare events in the melanoma sentinel lymph nodes, the current RT-PCR assays are not clinically useful for the diagnostics of melanoma micrometastasis. Hoon et al. proposed a multimarker panel, including cancer-specific markers, for RT-PCR assay in order to increase assay specificity (11). The identification of novel melanoma-specific markers remains one of the key objectives in melanoma research.

High-density microarrays have been applied to simultaneously monitor the expression of thousands of genes in biological samples. Studies have resulted in the identification of genes differentially expressed in benign and malignant lesions (12), as well as genes that might be of prognostic value (13). In their pioneering work, Bittner et al. (14) did gene expression profiling of malignant melanoma, using a microarray containing probes for 8,150 cDNAs. These researchers identified several genes that might be associated with aggressive tumor behavior. In the recent work of Hoek et al. (15), comparison of gene expression profiles of a few melanoma and normal melanocyte cell lines led to the identification of differentially expressed genes and pathways modulated in melanoma. In this study, we report the gene expression profiling of an extensive set of clinically relevant tissue samples. Forty-five primary malignant melanomas, 18...
benign skin nevi, and 7 normal skin tissues were hybridized on an Affymetrix Hu133A microarray (Santa Clara, CA) containing 22,000 probe sets. Differentially expressed genes in malignant melanoma, as compared with benign tissue, were identified. A one-step quantitative RT-PCR assay was used to test a combination of two melanoma-specific genes, PLAB and L1CAM, in a panel of clinically relevant samples that included primary malignant melanoma, benign nevi, melanoma lymph node metastasis and melanoma-free lymph node samples.

**Materials and Methods**

**Tissue samples.** Fresh-frozen malignant melanoma, benign skin nevi, normal skin, melanoma lymph node metastasis, and melanoma-free lymph node samples were obtained from Genomics Collaborative, Inc. (Cambridge, MA), Asterand (Detroit, MI), Cliniomics (Pittsfield, MA), Proteogenex (Los Angeles, CA), Ardais (Lexington, MA), and Impath (Westborough, MA). All tissue vendors declared that tissue specimens used in the presented study were collected according to an Institutional Review Board–approved protocol of corresponding hospitals and principles of bioethics. Patient demographics and pathology information were also collected. The histopathologic features of each sample were reviewed to confirm diagnosis and to estimate sample preservation and tumor content. Melanoma and benign nevi primary tissues chosen for microarray analysis had melanocyte content of >50% with no mixed histology. Melanoma-positive lymph nodes were collected from malignant melanoma patients and the diagnosis of melanoma was confirmed by H&E in combination with immunohistochemistry ($100 and HMB45). Melanoma-free lymph nodes derived from patients that did not have melanoma in their clinical history and absence of melanoma was confirmed by H&E and immunohistochemistry using antibodies for S100 and HMB45.

**RNA isolation and microarray hybridization.** Qiagen RNaseasy mini kit (Qiagen Inc., Valencia, CA) was used with a modified protocol to minimize the residual melanin in the RNA sample. For melanocyte-containing tissues, four replicate tissue samples derived from individual patients, each weighed ~5 mg, were used and processed separately. Tissue samples were homogenized in 1.0 mL RLT buffer (Qiagen) containing 10 μL of β-mercaptoethanol (Sigma Chemical Co., St. Louis, MO) by a mechanical homogenizer (UltraTurrax T8, IKA-Werke, Staufen, Germany). Following homogenization, samples were loaded on Qiagen RNaseasy columns and followed by centrifugation. After discarding the flow-through, 700 μL of RW1 buffer was added. The column was kept at room temperature for 5 minutes and then centrifuged; this step was repeated thrice. Then we followed the standard Qiagen RNasey mini kit protocol. To remove RNA from the silica gel membrane, a two-step elution was done. The total RNA derived from the same individual patient tissue was pooled and used for further analysis.

Standard Trizol protocol was used for RNA isolation from tissues that do not contain a significant proportion of melanocytes. Tissue was homogenized in Trizol reagent (Invitrogen, Carlsbad, CA). After centrifugation, the top liquid phase was collected and total RNA was precipitated with isopropyl alcohol at −20°C. RNA pellets were washed with 75% ethanol, resolved in water and stored at −80°C until use. The RNA quality was examined with an Agilent 2100 Bioanalyzer RNA 6000 Nano Assay (Agilent Technologies, Palo Alto, CA).

Labeled cRNA was prepared and hybridized with the high-density oligonucleotide array Hu133A Gene Chip (Affymetrix) containing a total of 22,000 probe sets according to standard manufacturer protocols. Arrays were scanned using Affymetrix protocols and scanners. For subsequent analysis, each probe set was considered as a separate gene. Expression values for each gene were calculated by using Affymetrix Gene Chip analysis software MAS 5.0. Arrays that met three quality control standards were used: “present” call was >35%, scale factor was <12 when scaled to a target intensity of 600, and background level was <150. A lower than usual percentage of “present” calls cutoff was chosen because it is difficult to isolate undegraded RNA from the skin samples (16), resulting in lower overall gene expression levels.

**Data analysis.** Gene expression data were filtered to include only genes that are called “present” in two or more samples. This filter was used to remove genes that did not change expression in the samples. Of the 22,000 genes presented on the array, 15,795 passed this filter and were used for hierarchical clustering. Prior to clustering, each gene expression signal was divided by the median expression in all the samples in the data set. This standardization step minimized the effect of the magnitude of gene expression and grouped together genes with similar expression patterns in the clustering analysis. Average linkage hierarchical clustering using Pearson correlation was done on both the genes and the samples using GeneSpring 6.1 software.

In order to identify differentially expressed genes, we compared the melanoma samples to the benign nevi and the normal skin samples separately. The first analysis consisted of the 45 melanoma and 7 normal skin samples; the second analysis consisted of 45 melanoma and 18 nevi samples. Significance analysis of microarrays (17), percentile analysis, and t test were used in gene selection (Supplementary Fig. S1). We selected a short list of genes with at least 10-fold overexpression in malignant melanoma, as compared with the benign specimens. The complete array data set has been submitted to the National Center for Biotechnology Information/Genbank GEO database (series entry GSE3189).

**Reverse transcription-PCR validation of microarray results.** Ten micrograms of total RNA from each sample were treated with DNase I and reverse-transcribed with oligo (dT) primer using Superscript II reverse transcriptase according to the manufacturer’s instructions (Invitrogen). A control gene PBGD was previously tested and reported as a housekeeping gene (18). Primers and MGB-probes for $2me20m (gp100), L1CAM, NTRK3, and the control gene PBGD were designed using Primer Express software (Applied Biosystems, Foster City, CA). The PLAB (M1C) gene probe was FAM-TAMRA-based because sequences were inadequate to design MGB based probes. Primer/probe sequences were as follows: $me20m (gp100) forward, 5′-TGTGT-CTCTGTGCGTATACAAAAAC-3′; $me20m (gp100) reverse, 5′-TCTCTGAG- CACGCTATAAGCT-3′; $me20m (gp100) probe, 5′-(6-FAM)-CTGG-CAGTGGTGGAC-3′; L1CAM forward, 5′-GCTGGGACTGAGCAA- GAAC-3′; L1CAM reverse, 5′-GGGACGAGATGCGAAGAAA-3′; L1CAM probe, 5′-(6-FAM)-TCCCCACACATGTC-3′; NTRK3 forward, 5′-GCCCGCGCACCCCTTATA-3′; NTRK3 reverse, 5′-AACCTGGC- CAGTGGGTAG-3′; NTRK3 probe, 5′-(6-FAM)-CAGATGCGTGT-3′; PLAB (M1C) forward, 5′-GGGACGAGATCCTGCTGCCA-3′; PLAB (M1C) reverse, 5′-GGGACGAGTTTCCCCTTGC-3′; PLAB (M1C) probe, 5′-(6-FAM)-CCCGCAGTGGTATCTGCGCCCGC(TAMRA)-3′; PLAB probe forward, 5′-CTGCTTCCGCTGATCACGCTC-3′; PLAB probe reverse, 5′-CAGACTCTCCGATCGAGTACA-3′; PBGD probe, 5′-(6-FAM)-CCGAGCGCGACCCCGTGTG-3′; PBGD probe reverse, 5′-(6-FAM)-PBGD forward, 5′-CCTCGTCTGCTGATCACGCTC-3′; PBGD probe reverse, 5′-CAGACTCTCCGATCGAGTACA-3′; PBGD probe.
interest and the control gene. The relative quantity of each target gene was represented as \( \Delta Ct \), which is equal to \( Ct \) of the target gene subtracted by \( Ct \) of the control gene.

**One-step quantitative reverse transcription-PCR assay on primary and lymph node samples.** Evaluation of expression of selected genes was carried out with one-step RT-PCR with RNA from primary melanoma, benign nevi, normal skin, melanoma lymph node metastasis, and melanoma-free lymph nodes. \( \beta\)-actin was used as a housekeeping gene to control for the input quantity and quality of RNA in the reactions. D Nas treatment was not used. Instead, primers or probes were designed to span an intron so they would not report on genomic DNA. Eight nanograms of total RNA were used for the RT-PCR. The total RNA was reverse-transcribed using 40 \( \times \) Multiscribe and RNase inhibitor mixed contained in the TaqMan one-step PCR Master Mix reagents kit (Applied Biosystems). The cDNA was then subjected to the 2 \( \times \) Master Mix without UNG, and PCR amplification was carried out on the ABI 7000HT sequence detection system (Applied Biosystems) in the 384-well block format using a 10 \( \mu \)L reaction size. The primer and probe concentrations were 4 and 2.5 \( \mu \)M, respectively. The reaction mixture was incubated at 48°C for 30 minutes for the reverse transcription, followed by a Amplitaq activation step of 95°C for 10 minutes and finally 40 cycles of 95°C for 15 seconds denaturing and 60°C for 1 minute annealing and extension. On each plate, a standard curve is generated from 8 pg to 80 ng, and when the \( R^2 \) value was \( >0.99 \), the cycle threshold (Ct) values were accepted. Sequences used in the reactions were as follows, each written in the 5’ to 3’ direction: L1CAM reverse, GCCACACACCACGCTCTCCTT; L1CAM probe, TGCGGCT. All primers and probes were optimized towards the same amplification efficiency.

\[ \text{Ct normalization has been widely used in clinical RT-PCR assays and } \]
\[ \text{was chosen as a straightforward method (19). For each gene marker, } \]
\[ t \text{ test was done on } \Delta \text{Ct between the melanoma and nonmelanoma samples, including both primary and lymph node samples. We then used the } \Delta \text{Ct to construct two scores for each patient. One score was derived from a combination of two melanoma-specific genes, PLAB and L1CAM; and the other score was derived from a combination of three conventional melanoma markers, tyrosinase, me20m, and MART1. The score was defined as the weighted sum of } \Delta \text{Ct values of the tested genes with the corresponding } t \text{ statistics as the weight. The two scores were normalized to have the same mean in order to compare them on the same scale.} \]

**Results**

**Patient clinical and pathologic characteristics.** The majority of primary melanoma included in the microarray analysis represent the early stage of disease and have thicknesses of <4 mm, which is consistent with the standard melanoma patient population (20). Patient demographic, clinical, and pathology characteristics are presented in Table 1. In addition, 77 malignant melanoma lymph node metastasis and 18 melanoma-free lymph node tissue samples were used for one-step quantitative PCR assay. Melanoma-positive lymph nodes included axillary, cervical, and inguinal lymph nodes with metastasis derived from epithelioid and spindle cell primary melanomas. Out of 18 melanoma-free lymph nodes, 10 were collected from other cancer patients but no cancer cells were found in these nodes by pathologists, and 8 lymph node were from nonmalignant lesions.

**Identification of genes differentially expressed in melanoma.** A total of 70 gene expression profiles were used for analysis. The median percentages of “present” calls for melanoma, benign and normal sample groups were 43.8%, 46.9%, and 41.7%. Sixty microarrays (86%) had scaling factors within 3-fold range of the minimum value. Ten chips with the scaling factors >3 were equally distributed between the sample categories, melanoma, benign, and normal.

Unsupervised hierarchical clustering results revealed a distinct separation of the melanoma, benign nevi, and normal skin samples (Fig. 1). We observed four clusters, including two clusters consisting of the majority of the melanoma samples (43 out of 45), the third cluster contained all 7 normal skin, 3 benign nevi, and 2 melanoma specimens and the fourth cluster, that included 14 of the 18 benign nevi samples. The source of the samples didn’t affect clustering. Specimens originating from different sources were clustered together according to the sample type (melanoma, benign, or normal). To further test the stability of the clustering patterns, we used an alternative cutoff on gene filtering prior to the cluster analysis. Specifically, we retained genes that have at least 10% “present” calls in each of the melanoma, benign nevi, and skin samples. With this cutoff, we obtained 15,306 genes and repeated hierarchical clustering. The cluster pattern on the patient samples was the same as the one from the 15,795 from the two “present” calls, confirming clustering stability.

The single nevi sample that clustered with the melanoma samples is an atypical nevi (moderate degree) sample with no melanoma in situ present. All three nevi samples that clustered with normal skin are compound nevi samples and one of them has a melanocyte content lower than the other nevi specimens. The melanoma samples themselves formed two clusters with 34 samples in the large and 9 samples in the smaller cluster. Samples that formed the small cluster represented epithelioid melanoma only and visually contained less melanin. The few stage III and IV tumors used in our study were all grouped in the small cluster. The large cluster was composed of specimens with epithelioid, spindle cell, and melanoma of mixed histology with more significant presence of melanin. The large cluster included stage I and II specimens only.

Distinct gene clusters were found in association with melanoma. This can be characterized by up-regulated (Fig. 1A, B, and C) and down-regulated (Fig. 1E) genes in the melanoma samples. At the same time, melanoma and benign nevi samples showed high expression of known melanocyte markers, such as MART-1 (Fig. 2D), confirming the comparable content of melanocytes in these samples and the inability of melanocyte-specific markers to differentiate them. Our data indicates that melanoma, benign nevi, and normal skin samples have distinct gene expression profiles and can be separated on a molecular basis.

In order to identify genes up-regulated in malignant melanoma, we applied significance analysis of microarrays, in combination with t test with Bonferroni correction and
percentile analysis (Supplementary Fig. S1). Bonferroni-adjusted t test and percentile analyses were used to address the multiple testing issue and the heterogeneity of the tumor samples, respectively. As the result of these analyses, 439 genes were selected (Supplementary Table S1). Out of 439 genes up-regulated in melanoma, we selected a short list of 33 genes that had >10-fold overexpression in the melanoma samples than that of the benign specimens. These include many genes with known association with malignant melanoma such as neurotrophic tyrosine kinase receptor, type 3 (NTRK3; ref. 21), L1 cell adhesion molecule (L1CAM; refs. 22, 23), silver homologue (me20m; ref. 24), as well as novel genes. Genes with >10-fold overexpression in melanoma are presented in Table 2.

We further selected three genes overexpressed in melanoma, including NTRK3, PLAB, and L1CAM, for quantitative real-time RT-PCR validation of the microarray results (Fig. 2). PLAB is a novel gene whose differential expression in melanoma, to the best of our knowledge, has not been previously reported. For L1CAM and NTRK3, differential expression in melanoma was shown at the protein level only (21–23). Moreover, we identified PLAB, L1CAM, and NTRK3 as the best combination, on a complementary basis, to separate melanoma from benign/normal tissues in our study. me20m is known as a melanoma-specific marker and was selected as a positive control. For the RT-PCR assay, we used a panel of 14 primary melanoma, 7 benign nevi, and 5 normal skin samples, isolated from the same tissues which were used for the microarray study. The expression value of each gene was normalized to the housekeeping control gene PBGD. The correlation coefficients between the RT-PCR and the microarray results for L1CAM, NTRK3, PLAB, and me20m are 0.79, 0.86, 0.87, and 0.88, respectively. This result indicates that the RT-PCR results are highly consistent with the microarray data.

**Table 1. Summary of patient information**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Melanoma patients (%)</th>
<th>Nevi patients (%)</th>
<th>Normal skin donors (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age</td>
<td>65.51 ± 14.55</td>
<td>33.17 ± 15.60</td>
<td>n/a</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>22 (48.9)</td>
<td>9 (50)</td>
<td>6</td>
</tr>
<tr>
<td>Male</td>
<td>23 (51.1)</td>
<td>9 (50)</td>
<td>1</td>
</tr>
<tr>
<td>Anatomic location</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Face</td>
<td>5 (11.1)</td>
<td>3 (17)</td>
<td></td>
</tr>
<tr>
<td>Scalp and neck</td>
<td>4 (8.9)</td>
<td>1 (6)</td>
<td></td>
</tr>
<tr>
<td>Trunk</td>
<td>9 (20)</td>
<td>10 (55)</td>
<td>6 (86)</td>
</tr>
<tr>
<td>Upper limb and shoulder</td>
<td>17 (37.8)</td>
<td>4 (22)</td>
<td></td>
</tr>
<tr>
<td>Lower limb and hip</td>
<td>6 (13.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin, NOS</td>
<td>4 (8.9)</td>
<td></td>
<td>1 (14)</td>
</tr>
<tr>
<td>Histologic diagnosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epithelioid cell</td>
<td>20 (44.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spindle cell</td>
<td>7 (15.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malignant melanoma, NOS</td>
<td>18 (40)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Compound nevus</td>
<td>8 (44)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intradermal nevus</td>
<td>5 (28)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atypical nevus</td>
<td>2 (11)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benign nevus, NOS</td>
<td>3 (17)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal skin</td>
<td></td>
<td></td>
<td>7 (100)</td>
</tr>
<tr>
<td>T stage (thickness)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1</td>
<td>11 (24.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T2</td>
<td>14 (31.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T3</td>
<td>16 (35.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T4</td>
<td>4 (8.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>42 (93.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N1</td>
<td>3 (6.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M0</td>
<td>44 (97.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M1</td>
<td>1 (2.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clark level</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>9 (20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>16 (35.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>12 (26.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>2 (4.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>n/a</td>
<td>6 (13.3)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
One-step quantitative reverse transcription-PCR assay for malignant melanoma. We examined a combination of two genes highly overexpressed in melanoma, PLAB and L1CAM, in a variety of clinical tissue samples containing malignant melanocytes (primary melanoma and melanoma lymph node metastasis), benign melanocytes (benign skin nevi), and normal samples (normal skin and melanoma-free lymph node) by RT-PCR. The primary tissues were the same as those used for the microarray study whereas all the lymph node specimens were derived from independent patients. Conventional melanoma markers, such as tyrosinase, gp100, and MART1 were also tested on the same samples as the controls because they are the most commonly used markers for the melanoma molecular assays in current clinical studies (25–27). Calculated scores were presented for PLAB and L1CAM (Fig. 3A) and for tyrosinase, me20m, and MART1 (Fig. 3B). The results showed a significant difference in the expression of PLAB and L1CAM between malignant melanoma samples (primary and lymph node metastasis) and benign nevi and normal lymph node. In contrast, three conventional markers showed similar expression levels in benign and melanoma samples. To further show the ability of these gene markers to separate benign and malignant tissues, we tested two cutoffs; the first was set-up as the highest score in primary normal samples, and the second as the highest score in benign nevi samples. For each cutoff, we estimated the sensitivity and specificity of the assay in the lymph node samples. With the cutoff determined on the normal samples, the new markers and the conventional markers gave sensitivities of 90% and 83%, respectively. Using of the cutoff determined on the benign samples, the sensitivities for the new and conventional markers were 88% and 42%. The results indicated that the new markers potentially have much better abilities to differentiate tissues containing benign and malignant melanocytes.

Discussion

We did gene expression profiling analysis of primary melanoma, benign nevi, and normal skin tissue specimens in order to find melanoma-specific gene markers for potential use in the lymph node–based molecular staging assay. Novel genes that are highly and differentially expressed in malignant melanoma samples were identified. The inclusion of benign nevi in the experimental design was key to our study. In contrast to normal skin, melanocyte content in benign nevi is close to that in melanoma. This was confirmed, in addition to histologic assessment, by the equally high expression levels of conventional melanoma markers such as tyrosinase and MART1 in both melanoma and nevi tissue specimens. Similar cellular compositions allowed us to monitor gene expression changes specifically associated with melanocyte malignant transformation, not just with melanocyte lineage differentiation. As a result, we identified novel genes specifically overexpressed in melanoma. One of the novel highly overexpressed in melanoma genes, prostate differentiation factor (PLAB, MIC1), is a member of the transforming growth factor-β superfamily and is also known to be associated with other malignancies.
Fig. 2. Microarray expression (A) and real-time RT-PCR validation data (B) of the selected genes. The first 14 samples from the left are the melanoma tissue samples (red), the next seven are benign nevi samples (yellow), and the last five are normal skin (blue). x-axis, intensity values for microarray plots; for PCR plots, x-axis is $2^{\Delta\Delta Ct}$, where $\Delta Ct$ is $Ct$ (target gene) – $Ct$ PBGD.
Among the genes overexpressed in melanoma, we observed many genes previously associated with the function and development of neural tissue, such as HEY1, L1CAM, SEMA3B, and NES. This suggests that dedifferentiation of melanocytes and activation of the processes related to a pluripotent progenitor cell, common to neural tissue cells and melanocytes, might be important for melanoma development and progression.

We have compared our results to the recent study of Haqq et al. (30). In their work, a cDNA microarray containing 20,862 probes was used to profile benign nevi, primary melanoma, and metastatic melanoma specimens. The sample set included metastatic and primary melanoma and benign nevi. Similar clustering results that separated the benign nevi and the primary malignant melanoma tissues were found in their study. Common genes were reported in both studies which could discriminate melanoma from benign nevi including kinesin-like 5 (KNSL5), prostate differentiation factor (PLAB), CITED1, osteopontin (SPP1), cathepsin B (CSTB), cadherin 3 (CDH3), presenilin 2 (PSEN2).

The results of our one-step RT-PCR assay showed that novel melanoma-specific genes, PLAB and L1CAM, were expressed not only in primary melanoma tissues but also in melanoma lymph node metastasis. Moreover, their ability to differentiate malignant melanoma from benign nevi made them better candidates than the conventional markers for the molecular test of melanoma diagnostics. With further validation in clinical studies, these genes could be developed as specific markers for a molecular staging assay to detect melanoma micrometastasis during a sentinel lymph node biopsy procedure.

### Table 2. Selected genes overexpressed in melanoma

<table>
<thead>
<tr>
<th>PSID</th>
<th>Gene accession</th>
<th>Description</th>
<th>Median expression in melanoma</th>
<th>Fold change (cancerous versus benign)</th>
<th>Fold change (cancerous versus skin)</th>
</tr>
</thead>
<tbody>
<tr>
<td>215025.at</td>
<td>S76476</td>
<td>trkC (alternatively spliced) human, brain (NTRK3)</td>
<td>2,365</td>
<td>149</td>
<td>93</td>
</tr>
<tr>
<td>215311.at</td>
<td>AL109696</td>
<td>full-length insert cDNA clone, EUROIMAGE 21920</td>
<td>10,093</td>
<td>86</td>
<td>30</td>
</tr>
<tr>
<td>213960.at</td>
<td>T87225</td>
<td>full-length insert cDNA clone, EUROIMAGE 51358</td>
<td>11,768</td>
<td>80</td>
<td>29</td>
</tr>
<tr>
<td>219478.at</td>
<td>NM.021197</td>
<td>WAP four-disulfide core domain 1 (WFDC1)</td>
<td>5,485</td>
<td>80</td>
<td>18</td>
</tr>
<tr>
<td>218839.at</td>
<td>NM.012258</td>
<td>hairy enhancer-of-split related with YRPW motif 1 (HEY1)</td>
<td>1,996</td>
<td>38</td>
<td>7</td>
</tr>
<tr>
<td>215115.x.at</td>
<td>AI613045</td>
<td>ets variant gene 6 (TEL oncogene)</td>
<td>12,421</td>
<td>34</td>
<td>15</td>
</tr>
<tr>
<td>221577.x.at</td>
<td>AF003934</td>
<td>prostate differentiation factor (PLAB)</td>
<td>4,897</td>
<td>28</td>
<td>38</td>
</tr>
<tr>
<td>213737.x.at</td>
<td>AF041811</td>
<td>ETV6-NTRK3 fusion</td>
<td>12,402</td>
<td>27</td>
<td>18</td>
</tr>
<tr>
<td>213638.at</td>
<td>AW054711</td>
<td>phosphatase and actin regulator 1 (PHACTR1)</td>
<td>1,827</td>
<td>26</td>
<td>102</td>
</tr>
<tr>
<td>204709.s.at</td>
<td>NM.004856</td>
<td>kinesin-like 5 (KNSL5)</td>
<td>312</td>
<td>24</td>
<td>16</td>
</tr>
<tr>
<td>221909.at</td>
<td>AW299700</td>
<td>hypothetical protein FLJ4627</td>
<td>243</td>
<td>22</td>
<td>17</td>
</tr>
<tr>
<td>204564.at</td>
<td>AI653981</td>
<td>L1 cell adhesion molecule (L1CAM)</td>
<td>9,677</td>
<td>21</td>
<td>15</td>
</tr>
<tr>
<td>209875.s.at</td>
<td>NM.033248</td>
<td>osteopontin (SPP1)</td>
<td>3,038</td>
<td>21</td>
<td>12</td>
</tr>
<tr>
<td>217624.at</td>
<td>AA464753</td>
<td>PDGFA associated protein 1 (PDAP1)</td>
<td>349</td>
<td>21</td>
<td>20</td>
</tr>
<tr>
<td>203071.at</td>
<td>NM.004636</td>
<td>semaphorin 3B (SEMA3B)</td>
<td>958</td>
<td>19</td>
<td>3</td>
</tr>
<tr>
<td>213587.s.at</td>
<td>AI884867</td>
<td>chromosome 7, open reading frame 32</td>
<td>10,416</td>
<td>18</td>
<td>9</td>
</tr>
<tr>
<td>221815.at</td>
<td>BE671816</td>
<td>abhydrolase domain containing 2 (ABHD2)</td>
<td>3,293</td>
<td>17</td>
<td>144</td>
</tr>
<tr>
<td>219578.s.at</td>
<td>NM.030594</td>
<td>similar to cytoplasmic polyadenylation element binding protein (CPEB1)</td>
<td>1,419</td>
<td>17</td>
<td>26</td>
</tr>
<tr>
<td>207144.s.at</td>
<td>NM.004143</td>
<td>bpp300-interacting transactivator, 1 (CITED1)</td>
<td>593</td>
<td>17</td>
<td>24</td>
</tr>
<tr>
<td>203069.at</td>
<td>NM.014849</td>
<td>synaptic vesicle glycoprotein 2A (SV2A)</td>
<td>560</td>
<td>15</td>
<td>13</td>
</tr>
<tr>
<td>218678.at</td>
<td>NM.024609</td>
<td>nestin (NES)</td>
<td>11,356</td>
<td>14</td>
<td>20</td>
</tr>
<tr>
<td>219152.x.at</td>
<td>NM.015720</td>
<td>podocalyxin-like 2 (PODXL2)</td>
<td>365</td>
<td>13</td>
<td>10</td>
</tr>
<tr>
<td>205447.s.at</td>
<td>BE222201</td>
<td>mitogen-activated protein kinase</td>
<td>567</td>
<td>13</td>
<td>5</td>
</tr>
<tr>
<td>213274.s.at</td>
<td>AA020826</td>
<td>cathepsin B (CTSB)</td>
<td>18,263</td>
<td>12</td>
<td>26</td>
</tr>
<tr>
<td>219555.s.at</td>
<td>NM.018455</td>
<td>uncharacterized bone marrow protein BM039</td>
<td>402</td>
<td>12</td>
<td>21</td>
</tr>
<tr>
<td>203827.at</td>
<td>NM.017983</td>
<td>WD40 repeat protein Interacting with phosphoinositides of 49 kDa (WIPI49)</td>
<td>3,380</td>
<td>11</td>
<td>8</td>
</tr>
<tr>
<td>205813.s.at</td>
<td>NM.000429</td>
<td>methionine adenosyltransferase l, a (MAT1A)</td>
<td>430</td>
<td>11</td>
<td>9</td>
</tr>
<tr>
<td>201850.at</td>
<td>NM.001747</td>
<td>capping protein, gelsolin-like (CAPG)</td>
<td>11,103</td>
<td>10</td>
<td>20</td>
</tr>
<tr>
<td>205373.at</td>
<td>NM.004389</td>
<td>catenin, a2 (CTNNA2)</td>
<td>579</td>
<td>10</td>
<td>8</td>
</tr>
<tr>
<td>214614.at</td>
<td>AI178662</td>
<td>homeobox HB9 (HLXB9)</td>
<td>542</td>
<td>10</td>
<td>9</td>
</tr>
<tr>
<td>213217.at</td>
<td>AU149572</td>
<td>adenylyl cyclase 2 (brain; ADCY2)</td>
<td>5,848</td>
<td>10</td>
<td>6</td>
</tr>
<tr>
<td>204014.at</td>
<td>NM.001394</td>
<td>dual specificity phosphatase 4 (DUSP4)</td>
<td>7,184</td>
<td>10</td>
<td>46</td>
</tr>
<tr>
<td>214893.x.at</td>
<td>AI421964</td>
<td>hyperpolarization activated cyclic nucleotide-gated potassium channel 2 (HCN2)</td>
<td>214</td>
<td>10</td>
<td>9</td>
</tr>
</tbody>
</table>
potential application of the genes is for the diagnosis of melanocyte lesions with uncertain pathologic features. We are evaluating the markers for use in sentinel lymph node biopsies determining the presence of melanoma disease and the prognosis of tumors.

Acknowledgments
We thank Drs. Robert T. Belly for helpful suggestions and discussions; Emma Du from Scripps Green Hospital for pathologic examination of the tissue specimens; Yi Zhang for statistical analysis; and Howard McLeod from Washington University School of Medicine for critical reading of the manuscript.

References
classification of cutaneous malignant melanoma by
profiling reveals novel pathways in the transformation
of melanocytes to melanomas. Cancer Res 2004;
64:5270–82.
16. Hipfel R, Garbe C, Schitte. RNA isolation from
human skin tissues for colorimetric differential display.
17. Tusher VG, Tibshirani R, Ghu G. Significance analysis
of microarrays applied to the ionizing radiation re-
rate normalization of real-time quantitative RT-PCR
data by geometric averaging of multiple internal con-
gene expression in archival paraffin-embedded
tissues: development and performance of a 92-gene
reverse transcriptase-polymerase chain reaction assay.
Am J Pathol 2004;164:35–42.
20. Aitken J, Elwood M. Population screening for melano-
ma: current evidence and a community based ran-
domized trial. In: Thompson JF, Morton DL, and
Kroon BBR, editors. Textbook of melanoma. London,
21. Xu X, Tahan SR, Pasha TR, Zhang PJ. Expression of
neurotrophin receptor TrkB in nevi and melanomas.
adhesion molecule (CD171) in development and
progression of human malignant melanoma. Cancer
of the cell adhesion molecule L1 is associated with me-
tastasis in cutaneous malignant melanoma. Eur J Can-
cer 2002;38:1708–16.
Fgidor CG. Molecular characterization of the melano-
cyte lineage specific antigen gp100. J Biol Chem 1994;
69:20126–33.
micrometastasis in sentinel lymph nodes from melanoma
patients: direct comparison of multimarker molec-
ular and immunopathological methods. Melanoma
26. Abrahamsen HN, Sorensen BS, Nexo E, Hamilton-
Dutoit SJ, Larsen J, Steeniche T. Pathologic assess-
ment of melanoma sentinel nodes: a role for molecular
analysis using quantitative real-time reverse transcrip-
tion-PCR for MART1 and tyrosinase messenger RNA.
27. Kammula US, Ghossein R, Bhattacharya S, Cot D.
Serial follow-up and prognostic significance of reverse
transcriptase-polymerase chain reaction-staged senti-
nel lymph nodes from melanoma patients. J Clin Oncol
28. Bae DS, Handa RJ, Yang RS, Campain JA. Gene
expression patterns as potential molecular biomarkers
for malignant transformation in human keratinocytes
treated with MNNG, arsenic or a metal mixture. Toxicol
delineation of secreted protein biomarkers overex-
pressed in cancer tissue and serum. Proc Natl Acad
expression signature of melanoma progression. Proc
Novel Genes Associated with Malignant Melanoma but not Benign Melanocytic Lesions